Faron Pharmaceuticals - Innovative medical solutions (Part 2)

Scientific articles seem to suppress those easily spiraling “yes-no” debates, so here’s a fresh article on AZA for a change:

MRD-Guided Azacitidine Delays Relapse in MDS and AML

https://www.hematologyadvisor.com/news/mrd-guided-azacitidine-myelodysplastic-syndrome-leukemia-aml-relapse/

Edit: As I understand it, does it emphasize the need to develop combination therapies?

7 Likes